Maze Therapeutics (MAZE) EBITDA Margin (2024 - 2026)
Maze Therapeutics (MAZE) posted EBITDA Margin of 132.76% for Q1 2026, down 781.11% sequentially from 19.49% in Q4 2024.
Maze Therapeutics (MAZE) EBITDA Margin (2024 - 2026) Analysis & Trends
Maze Therapeutics has reported EBITDA Margin for 2 years, with the latest figure at 132.76% in Q1 2026.
- Quarterly EBITDA Margin changed N/A year-over-year to 132.76% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 670.26% (down 63307.0% YoY) and the FY2024 annual result came in at 383.91%, changed N/A from the prior year.
- EBITDA Margin retreated to 132.76% in Q1 2026 per MAZE's latest filing, from 19.49% in the prior quarter.
- Over five years, EBITDA Margin peaked at 930.37% in Q2 2024 and troughed at 969.16% in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Maze Therapeutics | 1.51 Bn | 1.51 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -132.77% |
| Dec 31, 2024 | 19.49% |
| Sep 30, 2024 | -969.16% |
| Jun 30, 2024 | 930.37% |